Department of Oral Surgery, Jagiellonian University Medical College, Kraków, Poland.
Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poland.
Adv Clin Exp Med. 2021 Mar;30(3):301-307. doi: 10.17219/acem/130907.
Odontogenic keratocysts (OKCs) are clinically aggressive lesions with relatively high recurrence rates. Dysregulation of functional equilibrium in the RANK/RANKL/OPG system is responsible for osteolysis associated with the development of OKCs. Previously published findings imply that immunoexpression of these 3 proteins may correlate with bone resorption activity in OKCs.
The rationale behind this study was to assess the potential for receptor activator of nuclear factor kappa-B (RANK), receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) expression, as well as RANKL/OPG expression ratio, to serve as prognostic indicators for OKC recurrence.
We investigated the immunoexpression patterns of RANK, RANKL and OPG, and their correlation with recurrence rates, in 41 patients with OKCs treated with enucleation.
We found no statistically significant differences between recurrent and non-recurrent cysts in terms of either: epithelial (p = 0.404) and stromal (p = 0.469) immunoreactivity of RANK; epithelial (p = 0.649) and stromal (p = 0.198) immunoreactivity of RANKL; or epithelial (p = 1) and stromal (p = 0.604) immunoreactivity of OPG. We also did not find significant differences in the distribution of cases with respect to ratios of RANKL/OPG immunostaining scores between recurrent and non-recurrent OKCs, both in the epithelium and in the connective tissue (p = 1 and p = 0.237, respectively).
Our results suggest that immunoexpression levels of RANK, RANKL and OPG at the time of pathological diagnosis, as well as the RANKL/OPG ratio, are not useful as prognostic markers for OKC recurrence.
牙源性角化囊肿(OKC)是一种临床侵袭性病变,其复发率相对较高。RANK/RANKL/OPG 系统功能平衡失调与 OKC 发展相关的骨质溶解有关。先前的研究结果表明,这 3 种蛋白的免疫表达可能与 OKC 中的骨吸收活性相关。
本研究的理论基础是评估核因子 κB 受体激活剂(RANK)、核因子 κB 受体激活剂配体(RANKL)和护骨素(OPG)的表达潜力,以及 RANKL/OPG 表达比值,作为 OKC 复发的预后指标。
我们研究了 41 例接受剜除术治疗的 OKC 患者中 RANK、RANKL 和 OPG 的免疫表达模式及其与复发率的关系。
我们发现,无论是在 RANK 的上皮(p=0.404)和基质(p=0.469)免疫反应性,还是在 RANKL 的上皮(p=0.649)和基质(p=0.198)免疫反应性,或者在 OPG 的上皮(p=1)和基质(p=0.604)免疫反应性方面,复发和非复发囊肿之间均无统计学显著差异。我们也没有发现复发和非复发 OKC 之间在 RANKL/OPG 免疫染色评分比值方面的病例分布存在显著差异,上皮和结缔组织中均为如此(p=1 和 p=0.237)。
我们的研究结果表明,在病理诊断时 RANK、RANKL 和 OPG 的免疫表达水平以及 RANKL/OPG 比值均不能作为 OKC 复发的预后标志物。